/
BRTX
$0.37+$0.00 (+0.11%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$9.4M
25M shares
52-week range
$0.16 – $1.89
12% from low
Sector
SERVICES-MISC HEALTH & ALLIED SERVICES, NEC
Exchange
NASDAQ
CS
Borrow rate
30.28%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-6.65
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $111.0K | $130.0K | $77.0K | $46.0K | $119.8K | $145.8K | $401.0K | $359.7K |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $28.1K | $23.8K |
| Gross profit | $111.0K | $130.0K | $77.0K | $46.0K | $119.8K | $145.8K | $372.9K | $335.9K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 93.0% | 93.4% |
| R&D | $1.5M | $1.7M | $876.8K | $729.1K | $3.5M | $4.0M | $5.3M | $10.1M |
| Operating income | −$7.6M | −$8.4M | −$2.8M | −$26.3M | −$18.9M | −$15.2M | −$11.6M | −$15.6M |
| EBITDA | −$9.1M | −$9.3M | −$9.5M | −$42.4M | −$13.1M | −$15.0M | −$8.8M | −$14.0M |
| Net income | −$12.5M | −$14.6M | −$11.3M | −$44.3M | −$13.2M | −$10.4M | −$9.0M | −$14.2M |
| Net margin | -11277.3% | -11267.6% | -14639.9% | -96311.5% | -11037.0% | -7145.2% | -2239.2% | -3959.4% |
| EPS (diluted) | -4269.37 | -3217.82 | -28.56 | -37.30 | -3.65 | -2.47 | -1.16 | -1.58 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1M | $-0.49 | $-0.72–$-0.27 | 1 |
| 2027 | $2M | $-0.41 | $-0.59–$-0.22 | 1 |
| 2028 | $3M | $-0.41 | $-0.49–$-0.33 | 2 |
| 2029 | $119M | $1.79 | $0.99–$2.60 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
BioRestorative Therapies, Inc. Common Stock (NV)
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
www.biorestorative.com- Employees
- 14
- IPO / List date
- Dec 22, 1997
- HQ
- MELVILLE, NY
Held by traders on TradeandTell
No one on the platform currently holds BRTX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-09-30 | 20,000 | $34.8K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2021-10-27 | 1-for-4000reverse |
| 2015-07-07 | 1-for-20reverse |
| 2013-04-15 | 1-for-50reverse |
Recent trades on TradeandTell
No one on the platform has traded BRTX yet.
